Patents Assigned to GENEVANT SCIENCES GMBH
-
Patent number: 11938191Abstract: Described herein are block copolymers, and methods of making and utilizing such copolymers. The described block copolymers are disruptive of a cellular membrane, including an extracellular membrane, an intracellular membrane, a vesicle, an organelle, an endosome, a liposome, or a red blood cell. Preferably, in certain instances, the block copolymer disrupts the membrane and enters the intracellular environment. In specific examples, the block copolymer is endosomolytic and capable of delivering an oligonucleotide (e.g., an mRNA) to a cell. Compositions comprising a block copolymer and an oligonucleotide (e.g., an mRNA) are also disclosed.Type: GrantFiled: May 1, 2020Date of Patent: March 26, 2024Assignee: GENEVANT SCIENCES GMBHInventors: Sean D. Monahan, Michael S. Declue, Pierrot Harvie, Russell N. Johnson, Amber E. Paschal, Mary G. Prieve, Debashish Roy, Charbel Diab, Michael E. Houston, Jr., Anna Galperin, Maher Qabar
-
Publication number: 20240065982Abstract: Certain embodiments of the invention provide lipid nanoparticles for delivery nucleic acid therapeutics to the lungs.Type: ApplicationFiled: July 8, 2021Publication date: February 29, 2024Applicant: GENEVANT SCIENCES GMBHInventors: James Heyes, Kieu Mong Lam, Lorne Ralph Palmer
-
Patent number: 11707483Abstract: Provided herein are micellic assemblies comprising a plurality of copolymers. In certain instauces, micellic assemblies provided herein are pH sensitive particles.Type: GrantFiled: September 23, 2019Date of Patent: July 25, 2023Assignees: UNIVERSITY OF WASHINGTON, GENEVANT SCIENCES GMBHInventors: Patrick S. Stayton, Allan S. Hoffman, Anthony Convertine, Craig L. Duvall, Danielle Benoit, Robert Overell, Paul H. Johnson, Anna S. Gall, Mary G. Prieve, Amber E. E. Paschal, Charbel Diab, Priyadarsi De
-
Patent number: 11684584Abstract: Disclosed are branched PEG molecules, including branched PEG-lipids and branched-PEG proteins, as well as related compositions and methods for making branched PEG molecules. Also disclosed are related compositions, systems, and methods for in vivo delivery of therapeutic and diagnostic agents.Type: GrantFiled: December 29, 2017Date of Patent: June 27, 2023Assignee: Genevant Sciences GmbHInventors: Debashish Roy, Jean-Rene E. Ella-Menye, Sean D. Monahan, Pierrot Harvie, Anna Galperin, Michael E. Houston, Mary G. Prieve
-
Publication number: 20230150926Abstract: Certain embodiments of the invention provide lipids useful for preparing lipid nanoparticles for delivering therapeutic agents to, e.g., hepatic stellate cells.Type: ApplicationFiled: March 12, 2021Publication date: May 18, 2023Applicant: GENEVANT SCIENCES GMBHInventors: James HEYES, Kieu Mong Lam, Richard J. Holland
-
Publication number: 20230139594Abstract: Certain embodiments of the invention provide lipids useful for preparing lipid nanoparticles for delivering therapeutic agents to, e.g., hepatic stellate cells.Type: ApplicationFiled: February 11, 2021Publication date: May 4, 2023Applicant: GENEVANT SCIENCES GMBHInventors: James HEYES, Kieu Mong LAM, Richard J. HOLLAND, Wenxuan ZHANG
-
Publication number: 20220387600Abstract: Provided herein are certain nucleic acids (e.g., double stranded siRNA molecules), as well as conjugates that comprise a targeting moiety, a double stranded siRNA, and optional linking groups. Certain embodiments also provide synthetic methods useful for preparing the conjugates. The conjugates are useful to treat certain diseases, such as liver fibrosis, e.g., in the setting of NASH or ASH.Type: ApplicationFiled: December 7, 2020Publication date: December 8, 2022Applicant: GENEVANT SCIENCES GMBHInventors: James HEYES, Richard J. HOLLAND, Mark WOOD, Alan D. MARTIN, Christine ESAU, Margrit SCHWARZ, Xin YE, Alice Hoy Lam LI, Christopher Justin PASETKA, David CROWE, Steven TYLER
-
Publication number: 20220288214Abstract: Provided herein are certain nucleic acids (e.g., double stranded siRNA molecules), as well as conjugates that comprise a targeting moiety, a double stranded siRNA, and optional linking groups. Certain embodiments also provide synthetic methods useful for preparing the conjugates. He conjugates are useful to treat certain diseases, such as acromegaly.Type: ApplicationFiled: October 23, 2020Publication date: September 15, 2022Applicant: GENEVANT SCIENCES GMBHInventors: Drew KONDRATOWICZ, James HEYES, Richard J. HOLLAND, Christine ESAU, Kevin MCCLINTOCK, Christopher Justin PASETKA, Mark WOOD, Alan D. MARTIN, Margrit SCHWARZ, David CROWE, Steven TYLER
-
Publication number: 20220168222Abstract: The invention provides lipid nanoparticles and formulations containing lipid nanoparticles.Type: ApplicationFiled: April 24, 2020Publication date: June 2, 2022Applicant: GENEVANT SCIENCES GMBHInventors: James HEYES, Adam JUDGE, Kieu Mong LAM, Alan D. MARTIN
-
Publication number: 20220031847Abstract: The invention provides methods and compositions for delivering a nucleic acid to a cell or the cytosol of the target cell. The method includes contacting the cell with, 1) a membrane-destabilizing polymer; and 2) a nucleic acid conjugate. The nucleic acid conjugate includes a targeting ligand bound to an optional linker and a nucleic acid.Type: ApplicationFiled: November 4, 2019Publication date: February 3, 2022Applicant: GENEVANT SCIENCES GMBHInventors: James HEYES, Richard J. HOLLAND, Adam JUDGE, Kieu Mong LAM
-
Patent number: 11219634Abstract: Disclosed are methods for delivering a therapeutic or diagnostic agent to the cytosol of a cell in a subject. The disclosed methods generally include administering to the subject an effective amount of a lipid nanoparticle comprising the therapeutic or diagnostic agent and an effective amount of a membrane-destabilizing polymer. Also disclosed are related compositions and delivery systems.Type: GrantFiled: January 21, 2016Date of Patent: January 11, 2022Assignee: Genevant Sciences GmbHInventors: Mary G. Prieve, Michael E. Houston, Jr., Pierrot Harvie, Sean D. Monahan
-
Publication number: 20210023235Abstract: Described herein are block copolymers, and methods of making and utilizing such copolymers. The described block copolymers are disruptive of a cellular membrane, including an extracellular membrane, an intracellular membrane, a vesicle, an organelle, an endosome, a liposome, or a red blood cell. Preferably, in certain instances, the block copolymer disrupts the membrane and enters the intracellular environment. In specific examples, the block copolymer is endosomolytic and capable of delivering an oligonucleotide (e.g., an mRNA) to a cell. Compositions comprising a block copolymer and an oligonucleotide (e.g., an mRNA) are also disclosed.Type: ApplicationFiled: May 1, 2020Publication date: January 28, 2021Applicant: GENEVANT SCIENCES GMBHInventors: Sean D. MONAHAN, Michael S. DeCLUE, Pierrot HARVIE, Russell N. JOHNSON, Amber E. PASCHAL, Mary G. PRIEVE, Debashish ROY, Charbel DIAB, Michael E. HOUSTON, JR., Anna GALPERIN, Maher QABAR
-
Patent number: 10660970Abstract: Described herein are block copolymers, and methods of making and utilizing such copolymers. The described block copolymers are disruptive of a cellular membrane, including an extracellular membrane, an intracellular membrane, a vesicle, an organelle, an endosome, a liposome, or a red blood cell. Preferably, in certain instances, the block copolymer disrupts the membrane and enters the intracellular environment. In specific examples, the block copolymer is endosomolytic and capable of delivering an oligonucleotide (e.g., an mRNA) to a cell. Compositions comprising a block copolymer and an oligonucleotide (e.g., an mRNA) are also disclosed.Type: GrantFiled: August 16, 2019Date of Patent: May 26, 2020Assignee: Genevant Sciences GmbHInventors: Sean D. Monahan, Michael S. DeClue, Pierrot Harvie, Russell N. Johnson, Amber E. Paschal, Mary G. Prieve, Debashish Roy, Charbel Diab, Michael E. Houston, Jr., Anna Galperin, Maher Qabar
-
Publication number: 20200147121Abstract: Provided herein are micellic assemblies comprising a plurality of copolymers. In certain instances, micellic assemblies provided herein are pH sensitive particles.Type: ApplicationFiled: September 23, 2019Publication date: May 14, 2020Applicants: University of Washington, GENEVANT SCIENCES GMBHInventors: Patrick S. Stayton, Allan S. Hoffman, Anthony Convertine, Craig L. Duvall, Danielle Benoit, Robert Overell, Paul H. Johnson, Anna S. Gall, Mary G. Prieve, Amber E.E. Paschal, Charbel Diab, Priyadarsi De
-
Patent number: 10646582Abstract: Described herein are block copolymers, and methods of making and utilizing such copolymers. The described block copolymers are disruptive of a cellular membrane, including an extracellular membrane, an intracellular membrane, a vesicle, an organelle, an endosome, a liposome, or a red blood cell. Preferably, in certain instances, the block copolymer disrupts the membrane and enters the intracellular environment. In specific examples, the block copolymer is endosomolytic and capable of delivering an oligonucleotide (e.g., an mRNA) to a cell. Compositions comprising a block copolymer and an oligonucleotide (e.g., an mRNA) are also disclosed.Type: GrantFiled: November 30, 2017Date of Patent: May 12, 2020Assignee: Genevant Sciences GmbHInventors: Sean D. Monahan, Michael S. DeClue, Pierrot Harvie, Russell N. Johnson, Amber E. Paschal, Mary G. Prieve, Debashish Roy, Charbel Diab, Michael E. Houston, Jr., Anna Galperin, Maher Qabar
-
Publication number: 20200078313Abstract: Disclosed are branched PEG molecules, including branched PEG-lipids and branched-PEG proteins, as well as related compositions and methods for making branched PEG molecules. Also disclosed are related compositions, systems, and methods for in vivo delivery of therapeutic and diagnostic agents.Type: ApplicationFiled: December 29, 2017Publication date: March 12, 2020Applicant: Genevant Sciences GmbH.Inventors: Debashish ROY, Jean-Rene E. ELLA-MENYE, Sean D. MONAHAN, Pierrot HARVIE, Anna GALPERIN, Michael E. HOUSTON, JR., Mary G. PRIEVE
-
Publication number: 20190388551Abstract: Described herein are block copolymers, and methods of making and utilizing such copolymers. The described block copolymers are disruptive of a cellular membrane, including an extracellular membrane, an intracellular membrane, a vesicle, an organelle, an endosome, a liposome, or a red blood cell. Preferably, in certain instances, the block copolymer disrupts the membrane and enters the intracellular environment. In specific examples, the block copolymer is endosomolytic and capable of delivering an oligonucleotide (e.g., an mRNA) to a cell. Compositions comprising a block copolymer and an oligonucleotide (e.g., an mRNA) are also disclosed.Type: ApplicationFiled: August 16, 2019Publication date: December 26, 2019Applicant: GENEVANT SCIENCES GMBHInventors: Sean D. MONAHAN, Michael S. DeCLUE, Pierrot HARVIE, Russell N. JOHNSON, Amber E. PASCHAL, Mary G. PRIEVE, Debashish ROY, Charbel DIAB, Michael E. HOUSTON, Anna GALPERIN, Maher QABAR
-
Patent number: 10420790Abstract: Provided herein are micellic assemblies comprising a plurality of copolymers. In certain instauces, micellic assemblies provided herein are pH sensitive particles.Type: GrantFiled: April 27, 2017Date of Patent: September 24, 2019Assignees: University of Washington, GENEVANT SCIENCES GMBHInventors: Patrick S. Stayton, Allan S. Hoffman, Anthony Convertine, Craig L. Duvall, Danielle Benoit, Robert Overell, Paul H. Johnson, Anna S. Gall, Mary G. Prieve, Amber E. E. Paschal, Charbel Diab, Priyadarsi De